|
1
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Howington JA, Blum MG, Chang AC, Balekian
AA and Murthy SC: Treatment of stage I and II non-small cell lung
cancer: diagnosis and management of lung cancer, 3rd ed: American
College of Chest Physicians evidence-based clinical practice
guidelines. Chest. 143(Suppl 5): e278S–e313S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Peters S, Zimmermann S and Adjei AA: Oral
epidermal growth factor receptor tyrosine kinase inhibitors for the
treatment of non-small cell lung cancer: comparative
pharmacokinetics and drug-drug interactions. Cancer Treat Rev.
40:917–926. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Krzakowski M, Lucas C and Gridelli C:
Fractionated scheme of oral vinorelbine as single-agent therapy or
in combination with cisplatin concomitantly with thoracic
radiotherapy in stage III non-small-cell lung cancer:
dose-escalation phase I trial. Clin Lung Cancer. 15:266–273. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ardizzoni A, Boni L, Tiseo M, et al:
Cisplatin-versus carboplatin-based chemotherapy in first-line
treatment of advanced non-small-cell lung cancer: an individual
patient data meta-analysis. J Natl Cancer Inst. 99:847–857. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
D’Addario G, Pintilie M, Leighl NB, Feld
R, Cerny T and Shepherd FA: Platinum-based versus
non-platinum-based chemotherapy in advanced non-small-cell lung
cancer: a meta-analysis of the published literature. J Clin Oncol.
23:2926–2936. 2005. View Article : Google Scholar
|
|
7
|
Rosell R, Lord RV, Taron M and Reguart N:
DNA repair and cisplatin resistance in non-small-cell lung cancer.
Lung Cancer. 38:217–227. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
|
|
9
|
Gao Y, Liu Z, Zhang X, He J, Pan Y, Hao F,
Xie L, Li Q, Qiu X and Wang E: Inhibition of cytoplasmic GSK-3β
increases cisplatin resistance through activation of Wnt/β-catenin
signaling in A549/DDP cells. Cancer Lett. 336:231–239. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Doble BW and Woodgett JR: GSK-3: tricks of
the trade for a multi-tasking kinase. J Cell Sci. 116:1175–1186.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Orford K, Crockett C, Jensen JP, Weissman
AM and Byers SW: Serine phosphorylation-regulated ubiquitination
and degradation of β-catenin. J Biol Chem. 272:24735–24738. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cohen P and Goedert M: GSK3 inhibitors:
development and therapeutic potential. Nat Rev Drug Discov.
3:479–487. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kolligs FT, Bommer G and Göke B:
Wnt/beta-catenin/tcf signaling: a critical pathway in
gastrointestinal tumorigenesis. Digestion. 66:131–144. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dvory-Sobol H, Sagiv E, Kazanov D,
Ben-Ze’ev A and Arber N: Targeting the active β-catenin pathway to
treat cancer cells. Mol Cancer Ther. 5:2861–2871. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei Y, Shen N, Wang Z, Yang G, Yi B, Yang
N, Qiu Y and Lu J: Sorafenib sensitizes hepatocellular carcinoma
cells to cisplatin via suppression of Wnt/β-catenin signaling. Mol
Cell Biochem. 381:139–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang WC, Chan CC, Wu SJ, Chen LC, Shen
JJ, Kuo ML, Chen MC and Liou CJ: Matrine attenuates allergic airway
inflammation and eosinophil infiltration by suppressing eotaxin and
Th2 cytokine production in asthmatic mice. J Ethnopharmacol.
151:470–477. 2014. View Article : Google Scholar
|
|
17
|
Yang Y, Xiu J, Zhang X, Zhang L, Yan K,
Qin C and Liu J: Antiviral effect of matrine against human
enterovirus 71. Molecules. 17:10370–10376. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Y, Xu Y, Ji W, Li X, Sun B, Gao Q and
Su C: Anti-tumor activities of matrine and oxymatrine: literature
review. Tumour Biol. 35:5111–5119. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Niu H, Zhang Y, Wu B, Zhang Y, Jiang H and
He P: Matrine induces the apoptosis of lung cancer cells through
downregulation of inhibitor of apoptosis proteins and the Akt
signaling pathway. Oncol Rep. 32:1087–1093. 2014.PubMed/NCBI
|
|
20
|
Li Y, Zhang ZN, Zhao HM, Tong ZC, Yang J,
Wang H and Liang XJ: Matrine inhibits the invasive properties of
human osteosarcoma cells by downregulating the ERK-NF-κB pathway.
Anticancer Drugs. 25:1035–1043. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie BS, He XX, Ai ZL and Yao SK:
Involvement of β-catenin in matrine-induced autophagy and apoptosis
in WB-F344 cells. Mol Med Rep. 9:2547–2553. 2014.PubMed/NCBI
|
|
22
|
Guo D, Chen NN, Zhou P, Pan B and Hou LB:
Suppressive effect of matrine on cell growth and decreases
beta-catenin-dependent transcriptional activity in hepatoma cell
line Hep3B. Zhong Yao Cai. 33:778–781. 2010.In Chinese. PubMed/NCBI
|
|
23
|
Jiang Z, Yin J, Fu W, Mo Y, Pan Y, Dai L,
Huang H, Li S and Zhao J: miRNA 17 family regulates
cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC.
PLoS One. 9:e946392014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He K, Xu T, Xu Y, Ring A, Kahn M and
Goldkorn A: Cancer cells acquire a drug resistant, highly
tumorigenic, cancer stem-like phenotype through modulation of the
PI3K/Akt/β-catenin/CBP pathway. Int J Cancer. 134:43–54. 2014.
View Article : Google Scholar
|
|
25
|
Nagano H, Tomimaru Y, Eguchi H, Hama N,
Wada H, Kawamoto K, Kobayashi S, Mori M and Doki Y: MicroRNA-29a
induces resistance to gemcitabine through the Wnt/β-catenin
signaling pathway in pancreatic cancer cells. Int J Oncol.
43:1066–1072. 2013.PubMed/NCBI
|
|
26
|
Shen DY, Zhang W, Zeng X and Liu CQ:
Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein
and reverses multi-drug resistance of cholangiocarcinoma. Cancer
Sci. 104:1303–1308. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Teng Y, Wang X, Wang Y and Ma D:
Wnt/β-catenin signaling regulates cancer stem cells in lung cancer
A549 cells. Biochem Biophys Res Commun. 392:373–379. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou H, Xu M, Gao Y, et al: Matrine
induces caspase-independent program cell death in hepatocellular
carcinoma through bid-mediated nuclear translocation of apoptosis
inducing factor. Mol Cancer. 13:592014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Green DR and Kroemer G: The
pathophysiology of mitochondrial cell death. Science. 305:626–629.
2014. View Article : Google Scholar
|
|
30
|
Zhang S, Zhang Y, Zhuang Y, Wang J, Ye J,
Zhang S, Wu J, Yu K and Han Y: Matrine induces apoptosis in human
acute myeloid leukemia cells via the mitochondrial pathway and Akt
inactivation. PLoS One. 7:e468532012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheung CH, Huang CC, Tsai FY, et al:
Survivin - biology and potential as a therapeutic target in
oncology. Onco Targets Ther. 6:1453–1462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Okamoto K, Okamoto I, Okamoto W, Tanaka K,
Takezawa K, Kuwata K, Yamaguchi H, Nishio K and Nakagawa K: Role of
survivin in EGFR inhibitor-induced apoptosis in non-small cell lung
cancers positive for EGFR mutations. Cancer Res. 70:10402–10410.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tian H, Liu S, Zhang J, et al: Enhancement
of cisplatin sensitivity in lung cancer xenografts by
liposome-mediated delivery of the plasmid expressing small hairpin
RNA targeting Survivin. J Biomed Nanotechnol. 8:633–641. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu Q, Chen B, Zhang X, Qian W, Ye B and
Zhou Y: Arsenic trioxide-enhanced, matrine-induced apoptosis in
multiple myeloma cell lines. Planta Med. 79:775–781. 2013.
View Article : Google Scholar : PubMed/NCBI
|
